Eating disorders are on the rise. GLP-1s could make things worse.
But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders.
Key points
- A new report suggests that the global incidence of anorexia nervosa and bulimia nervosa shot up between 1990 and 2023—by a whopping 71%.
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.
GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 2 articles from 1 outlet
MIT Technology ReviewOctober 30, 2026, 11:30 AM UTC →
MIT Technology ReviewOctober 30, 2026, 9:00 AM UTC →
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.